231 related articles for article (PubMed ID: 34678705)
1. Application of liquid chromatography coupled to data-independent acquisition mass spectrometry for the metabolic profiling of N-ethyl heptedrone.
Mazzarino M; Camuto C; Comunità F; de la Torre X; Stacchini C; Botrè F
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122989. PubMed ID: 34678705
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies.
Mazzarino M; Biava M; de la Torre X; Fiacco I; Botrè F
Anal Bioanal Chem; 2013 Jun; 405(16):5467-87. PubMed ID: 23604525
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the phase I and phase II metabolic profile of tolvaptan by in vitro studies and liquid chromatography-mass spectrometry profiling: Relevance to doping control analysis.
Mazzarino M; Buccilli V; de la Torre X; Fiacco I; Palermo A; Ughi D; Botrè F
J Pharm Biomed Anal; 2017 Oct; 145():555-568. PubMed ID: 28759864
[TBL] [Abstract][Full Text] [Related]
4. Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MS
Michely JA; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2017 Feb; 409(6):1681-1695. PubMed ID: 27933361
[TBL] [Abstract][Full Text] [Related]
5. Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS).
Steuer AE; Williner E; Staeheli SN; Kraemer T
Drug Test Anal; 2017 Jul; 9(7):1085-1092. PubMed ID: 27736030
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MS
Caspar AT; Gaab JB; Michely JA; Brandt SD; Meyer MR; Maurer HH
Drug Test Anal; 2018 Jan; 10(1):184-195. PubMed ID: 28342193
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profiling of five flavonoids from Dragon's Blood in human liver microsomes using high-performance liquid chromatography coupled with high resolution mass spectrometry.
Li Y; Zhang Y; Wang R; Wei L; Deng Y; Ren W
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 May; 1052():91-102. PubMed ID: 28376352
[TBL] [Abstract][Full Text] [Related]
8. Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP).
Meyer MR; Holderbaum A; Kavanagh P; Maurer HH
J Mass Spectrom; 2015 Oct; 50(10):1163-74. PubMed ID: 26456786
[TBL] [Abstract][Full Text] [Related]
9. Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MS
Wink CS; Michely JA; Jacobsen-Bauer A; Zapp J; Maurer HH
Drug Test Anal; 2016 Oct; 8(10):1005-1014. PubMed ID: 26811026
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.
Michely JA; Helfer AG; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2015 Oct; 407(25):7831-42. PubMed ID: 26297461
[TBL] [Abstract][Full Text] [Related]
11. LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques.
Caspar AT; Westphal F; Meyer MR; Maurer HH
Anal Bioanal Chem; 2018 Jan; 410(3):897-912. PubMed ID: 28762065
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
13. Metabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry.
Seo H; Kim IS; Kim YH; Yoo HH; Hong J
Int J Legal Med; 2019 May; 133(3):833-841. PubMed ID: 30090972
[TBL] [Abstract][Full Text] [Related]
14. In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry.
Mortelé O; Vervliet P; Gys C; Degreef M; Cuykx M; Maudens K; Covaci A; van Nuijs ALN; Lai FY
J Pharm Biomed Anal; 2018 May; 153():158-167. PubMed ID: 29494888
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples.
Noble C; Mardal M; Bjerre Holm N; Stybe Johansen S; Linnet K
Drug Test Anal; 2017 Aug; 9(8):1182-1191. PubMed ID: 27935260
[TBL] [Abstract][Full Text] [Related]
16. In vitro metabolic profile of mexedrone, a mephedrone analog, studied by high- and low-resolution mass spectrometry.
Camuto C; Guglielmelli A; De-Giorgio F; de la Torre X; Mazzarino M; Marti M; Botrè F
Drug Test Anal; 2022 Feb; 14(2):269-276. PubMed ID: 34652887
[TBL] [Abstract][Full Text] [Related]
17. In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models.
Grafinger KE; Stahl K; Wilke A; König S; Weinmann W
Drug Test Anal; 2018 Oct; 10(10):1607-1626. PubMed ID: 29971945
[TBL] [Abstract][Full Text] [Related]
18. Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography-linear ion trap-mass spectrometry (LC-MS(n)).
Meyer MR; Dinger J; Schwaninger AE; Wissenbach DK; Zapp J; Fritschi G; Maurer HH
Anal Bioanal Chem; 2012 Jan; 402(3):1249-55. PubMed ID: 22065349
[TBL] [Abstract][Full Text] [Related]
19. Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS(n) techniques.
Welter J; Brandt SD; Kavanagh P; Meyer MR; Maurer HH
Anal Bioanal Chem; 2015 May; 407(12):3457-70. PubMed ID: 25711990
[TBL] [Abstract][Full Text] [Related]
20. Metabolic profiling of synthetic cannabinoid 5F-ADB by human liver microsome incubations and urine samples using high-resolution mass spectrometry.
Yeter O; Ozturk YE
Drug Test Anal; 2019 Jun; 11(6):847-858. PubMed ID: 30610752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
